Cargando…
ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Colégio Brasileiro de Cirurgia Digestiva
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983529/ https://www.ncbi.nlm.nih.gov/pubmed/33759958 http://dx.doi.org/10.1590/0102-672020200004e1568 |
_version_ | 1783667923529760768 |
---|---|
author | CZECZKO, Leticia Elizabeth Augustin RIBAS, Carmen Australia Paredes Marcondes CZECZKO, Nicolau Gregori SKARE, Thelma Larocca YAMAKAWA, Camila Kienen GIONEDIS, Guilherme VASCONCELOS, Cecilia BREMER, Fabiola Pabst CASTOLDI, Diogo Francesco GASSER, Martin WAAGA-GASSER, Ana Maria |
author_facet | CZECZKO, Leticia Elizabeth Augustin RIBAS, Carmen Australia Paredes Marcondes CZECZKO, Nicolau Gregori SKARE, Thelma Larocca YAMAKAWA, Camila Kienen GIONEDIS, Guilherme VASCONCELOS, Cecilia BREMER, Fabiola Pabst CASTOLDI, Diogo Francesco GASSER, Martin WAAGA-GASSER, Ana Maria |
author_sort | CZECZKO, Leticia Elizabeth Augustin |
collection | PubMed |
description | BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas. METHODS: A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics. RESULTS: Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia. CONCLUSIONS: CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis. |
format | Online Article Text |
id | pubmed-7983529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Colégio Brasileiro de Cirurgia Digestiva |
record_format | MEDLINE/PubMed |
spelling | pubmed-79835292021-03-31 ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? CZECZKO, Leticia Elizabeth Augustin RIBAS, Carmen Australia Paredes Marcondes CZECZKO, Nicolau Gregori SKARE, Thelma Larocca YAMAKAWA, Camila Kienen GIONEDIS, Guilherme VASCONCELOS, Cecilia BREMER, Fabiola Pabst CASTOLDI, Diogo Francesco GASSER, Martin WAAGA-GASSER, Ana Maria Arq Bras Cir Dig Original Article BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas. METHODS: A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics. RESULTS: Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia. CONCLUSIONS: CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis. Colégio Brasileiro de Cirurgia Digestiva 2021-03-23 /pmc/articles/PMC7983529/ /pubmed/33759958 http://dx.doi.org/10.1590/0102-672020200004e1568 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Original Article CZECZKO, Leticia Elizabeth Augustin RIBAS, Carmen Australia Paredes Marcondes CZECZKO, Nicolau Gregori SKARE, Thelma Larocca YAMAKAWA, Camila Kienen GIONEDIS, Guilherme VASCONCELOS, Cecilia BREMER, Fabiola Pabst CASTOLDI, Diogo Francesco GASSER, Martin WAAGA-GASSER, Ana Maria ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title | ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title_full | ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title_fullStr | ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title_full_unstemmed | ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title_short | ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? |
title_sort | are stem cell marker expression and cd133 analysis relevant to differentiate colorectal cancer? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983529/ https://www.ncbi.nlm.nih.gov/pubmed/33759958 http://dx.doi.org/10.1590/0102-672020200004e1568 |
work_keys_str_mv | AT czeczkoleticiaelizabethaugustin arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT ribascarmenaustraliaparedesmarcondes arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT czeczkonicolaugregori arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT skarethelmalarocca arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT yamakawacamilakienen arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT gionedisguilherme arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT vasconceloscecilia arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT bremerfabiolapabst arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT castoldidiogofrancesco arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT gassermartin arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer AT waagagasseranamaria arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer |